Sarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate Developments

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. NKE
3. PANW
4. CL
5. SNDK
6. TAP
7. DELL
8. ROIV
9. ANET
10. BE

Go back to Sarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate Developments

Oppenheimer Continues to Expect Sarepta (SRPT) Eteplirsen Approval in the Next Few Months

July 20, 2016 9:48 AM EDT

Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) following results. The analyst continues to expected FDA approval in the next few months.

Gilson commented, "Sarepta on July 19 reported 2Q16 financial results, ending the... More